A genetically engineered Newcastle disease virus, which harms chickens but not humans, kills prostate cancer cells of all kinds, researchers at the Virginia-Maryland Regional College of Veterinary Medicine have discovered.
The study was conducted by Dr. Elankumaran Subbiah, associate professor of virology in the Department of Biomedical Sciences and Pathobiology, along with Dr. Siba Samal, associate dean and chairman of the University of Maryland's Department of Veterinary Medicine, and Shobana Raghunath, a graduate student in Subbiah's laboratory.
"This potential treatment is available for immediate pre-clinical and clinical trials, but these are typically not done at the university level," Subbiah said.
"We are looking for commercial entities that are interested in licensing the technology for human clinical trials and treatment. Newcastle disease virus has yet to be tested as a treatment for prostate cancer in patients," he added.
About one in six men will develop prostate cancer. Patients typically receive hormone treatments or chemotherapy, both of which have adverse side effects. Subbiah hopes that the development of new treatment methodologies will not only better fight prostate cancer, but also lessen the side effects commonly associated with hormone treatments and chemotherapy.
Scientists first documented the cancer-fighting properties of Newcastle disease virus in the 1950s, but it is only with recent advances in reverse genetics technology that they have turned to the genetically engineered virus as a possible treatment.
"We modified the virus so that it replicates only in the presence of an active prostate-specific antigen and, therefore, is highly specific to prostate cancer. We also tested its efficacy in a tumor model in vitro," Subbiah said.
"The recombinant virus efficiently and specifically killed prostate cancer cells, while sparing normal human cells in the laboratory, but it would take time for this to move from the discovery phase to a treatment for prostate cancer patients," he stated.
Earlier human clinical trials for other types of cancer with naturally occurring strains of Newcastle disease virus required several injections of the virus in large quantities for success.
Subbiah believes that the recombinant virus would be able to eradicate prostate cancer in much lower doses. It would also seek out metastatic prostate cancer cells and remove them.
Because it is cancer cell-type specific, "the recombinant virus will be extremely safe and can be injected intravenously or directly into the tumor," Subbiah added.
The research appeared in the April 2013 issue of the Journal of Virology.